Screener / SEC EDGAR /CIK 0001109354 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Lab Instruments

Bruker Corp BRKR

Compare with peers Embed
The 10-K against last year's

154 changes: 42 added, 25 removed, 82 reworded, 5 quiet changes

10-K Feb 27, 2026 vs Mar 3, 2025

10-K 0001193125-26-082523 (Feb 27, 2026) vs 10-K 0000950170-25-030897 (Mar 3, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

192 paragraphs · 23 new · 81 reworded · 7 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 37 · 49% changed Every version of it
We have experienced supply chain interruptions or increased costs as a result of general global economic conditions, including economic instability, changes to governmental policies and programs, changes in tax laws and regulations, export controls, economic sanctions and trade restrictions, including those related to the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, changes to trade policies, including higher tariff rates and customs duties imposed or that may be imposed by the new presidential administration in the U.S., continued threat of terrorism and heightened security and military action in response thereto, or any other current or future acts of terrorism, war (such as the ongoing geopolitical tensions and military conflicts in China and other regions between the U.S. and China ), a tight labor market and other factors, including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in our products including microelectronic components and increased difficulties in our ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in our products, including limited source components, have and can result in significant additional costs and inefficiencies in manufacturing. A shortage of key components has in the past and may in the future cause a significant disruption to our production activities, which could have a substantial adverse effect on our financial condition or results of operations. If we are unsuccessful in resolving any such component shortages in a timely manner, we could experience a significant adverse impact on the timing of our revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which could have a material adverse impact on our operating results.
Paragraph 74 · 47% changed Every version of it
The market for discovery and analysis tools is characterized by rapid technological change and frequent new product introductions. Rapidly changing technology could make some or all of our product lines obsolete unless we are able to continually improve our existing products and develop new products. Because substantially all of our products are based on our technology platforms, including magnetic resonance technology, mass spectrometry technology, X-ray technology, atomic force microscopy technology, fluorescence microscopy technology, spatial biology technologies, stylus and optical metrology technology and infrared technology, we are particularly vulnerable to any technological advances that would make these techniques obsolete as the basis for analytical systems in any of our markets. To meet the evolving needs of our customers, we must rapidly and continually enhance our current and planned products and services and develop and introduce new products and services. In addition, our product lines are based on complex technologies that are subject to rapid change as new technologies are developed and introduced in the marketplace. We may have difficulty in keeping abreast of the rapid changes affecting each of the different markets we serve or intend to serve. If we fail to develop and introduce products in a timely manner in response to changing technology, market demands or the requirements of our customers, our product sales may decline, and we could experience significant losses.
Paragraph 124 · 45% changed Every version of it
There has been increased focus by federal, international, state and local regulatory and legislative bodies to combat and/or limit the effects of climate change through a variety of means, including regulating GHG emissions (and requirements to disclose climate-related risks and metrics, including GHG emissions), policies mandating or promoting the use of renewable or zero-carbon energy and sustainability initiatives, and additional taxes on fuel and energy. These regulations, and changes to them, could increase our cost of compliance, and our failure to comply could result in the imposition of significant fines, suspension of production, alteration of product processes, cessation of operations or other actions which could materially and adversely affect our business, financial condition and results of operation.
Paragraph 164 · 44% changed Every version of it
Our manufacturing, product development and research and development operations and processes involve the controlled use of certain hazardous materials. In addition, we own and/or lease a number of facilities, some of which have been in operation for many decades, where we or others may have used substances or generated and disposed of wastes which are considered hazardous or may be considered hazardous in the future. We also have acquired various companies which historically may have used certain hazardous materials, and which may have owned and/or leased facilities at which hazardous materials have been used. For all of these reasons, we are subject to federal, state, foreign, and local laws and regulations governing the use, manufacture, storage, transportation, handling, treatment, remediation, and disposal of hazardous materials and certain waste products. We have potential liability under these laws and regulations with respect to the remediation of past contamination in certain of the facilities we now own or lease. Additionally, in the future our facilities and the disposal sites owned by others to which we send or have sent waste, may be identified as contaminated and require remediation. Accordingly, we may become subject to additional compliance costs or environmental liabilities which may be significant and could materially harm our results of operations or financial condition.
Paragraph 6 · 42% changed Every version of it
•A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding, funding including NIH grants, grants from the U.S. National Institutes of Health (“NIH”), the National Science Foundation (“NSF”), and any the Department of Energy (“DOE”). The current reduction in, modification in the level of the terms funding and allowable overhead rates of, or delay in such research funding, could adversely affect has had a material adverse effect on our U.S. academic and governmental customers, and our revenues business, results of operations and financial performance; condition, and may continue to do so in the foreseeable future;
Paragraph 130 · 42% changed Every version of it
The unpredictability and fluctuation of our quarterly results Series A Mandatory Convertible Preferred Stock may adversely affect the trading market price of our common stock.
Paragraph 102 · 41% changed Every version of it
and enacting local legislation codifying the provisions that all 142 countries in the Inclusive Framework agreed to by consensus. The EU member states have agreed to adopt these rules in two stages with the first component will be effective on January 1, 2024, while the second component became effective on January 1, 2025. Non-EU countries have enacted or are expected to enact legislation on various timelines. Certain While certain countries in which we operate have already enacted legislation to adopt the Pillar Two framework, while framework and, several other countries are expected to also implement similar legislation with varying effective dates in the future, the U.S. has withdrawn support for Pillar Two. In June 2025, the U.S. Department of the Treasury and the other G7 countries (including Canada, France, Germany, Italy, Japan, the United Kingdom and the European Union) released a joint statement announcing an understanding regarding a proposed “side-by-side” solution that would exempt U.S.-parented multinational businesses from certain provisions of the global minimum tax, and the OECD released a draft proposal, dated August 13, 2025, to exclude U.S. multinational companies from certain minimum tax enforcement measures. However, no agreement regarding implementation of the proposal has yet been reached. We will continue to monitor the implementation of the Inclusive Framework agreement by the remaining countries in which we operate or may operate in the future. When We are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these remaining countries; however, when and how this framework is adopted or enacted by the various countries in which we do business will increase tax complexity and may increase uncertainty and adversely affect our provision for income taxes in the U.S. and non-U.S. jurisdictions.
Paragraph 50 · 40% changed Every version of it
A substantial portion of our revenue in the United States is derived from academic and governmental institutions, research organizations and other entities that may rely in part or in whole on academic and government funding, including grants from the U.S. National Institutes of Health (NIH) NIH, NSF and DOE, and other U.S. government agencies. Government However, during fiscal year 2025, under the current U.S. administration there has been significant disruption in U.S. academic funding may fluctuate for high-end research instrumentation used in academic and is subject to annual appropriations and budgetary constraints, and there is no assurance that such funding will continue at current levels. If U.S, medical research. U.S. academic and governmental researchers experience experiencing material reductions or delays in government funding, or modifications of the terms or conditions of funding, including allowable overhead rates, they may reduce have reduced or delay delayed their purchases of our products and services, which has adversely affected our business and results of operations. While the recent dispute settlements between a limited number of major universities and the U.S. federal government may allow for the resumption of certain grants for scientific and medical research, we expect the reduced level of funding may continue for the foreseeable future, which could continue to have a material adverse effect on our revenues business, results of operations and financial performance. condition.

MD&A

98 paragraphs · 19 new · 45 reworded · 18 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 36 · 50% changed
•Non-GAAP GAAP gross profit and gross profit margin as GAAP to non-GAAP gross profit margin excluding the impact of non-GAAP adjustments. and gross profit margin:
Paragraph 38 · 50% changed
•Non-GAAP operating income as GAAP operating income excluding and operating margin to non-GAAP adjustments. operating income and operating margin:
Paragraph 84 · 50% changed
Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, and are disclosed in Note 2, Summary of Significant Accounting Policies in the notes the consolidated financial statements. U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period.
Paragraph 64 · 48% changed
The increase in interest and other income (expense), net during the year ended December 31, 2024, as compared to the same period in 2023 2025, was primarily due to higher interest expense and lower foreign exchange differences on the revaluation of $47.9 million monetary items, partially offset by the income on settlement of interest rate swap agreement. We expect interest expense to decrease in 2026 primarily due to increased borrowings, lower debt levels following the repayments made during 2025. Refer to Note 13, Interest and impairment of certain minority investments of $24.6 million, offset by higher foreign currency exchange gains of 23.7 million driven by strengthening of the U.S. dollar against Other Income (Expense), net for more details on our interest and other currencies. income (expense), net.
Paragraph 47 · 48% changed
Revenue increases were driven by strong demand for our differentiated instruments and solutions and revenue growth from acquisitions. The BSI BioSpin Segment overall revenue increase during the year ended December 31, 2025, was primarily due to demand for our instruments across academia, government driven mostly by ELITechGroup within the BSI CALID Microbiology & Infection Diagnostics division and biopharma markets. The NanoString within the BSI BioSpin Segment also saw increased NANO Bruker Spatial Biology division, partially offset by organic revenue from the Chemspeed acquisition. We had revenue from four gigahertz-class NMR systems each in fiscal 2024 and fiscal 2023. decline. The BSI CALID Segment increase in revenue increase reflected strong demand for our differentiated instruments, primarily, in our was driven by increased volumes from the Optics and Microbiology & Infection Diagnostics, driven by Diagnostics divisions, with increased activity in the applied market Security Detection products, the MALDI BioTyper Biotyper business, and the ELITechGroup molecular diagnostics business, which was acquired in 2024, the second quarter of 2024. BSI Nano Segment revenue decline was driven by weaker demand in the academic and government research and industrial markets for our analytical instruments and the Nano Surfaces and Metrology division, partially offset by NanoString, which was acquired in the second quarter of 2024. BSI BioSpin decrease in revenue was primarily driven by fewer GHz-class NMR system sales in 2025 compared to 2024 (two in 2025 versus four in 2024), weaker demand in the biopharma market and NMR instruments, partially offset by stronger demand in our lab automation products. The BEST revenue decrease was driven mainly by a softness in the clinical MRI market, as well as our Optics IR/NIR/Raman businesses. This was partially offset by softness in academia and government markets as well as our China market. The BSI NANO Segment revenue increase was driven by a strong demand in its semiconductor metrology market as well as revenue increases from prior-year comparison for the NanoString and Bruker Cellular acquisitions offset by soft demand from biopharma. BEST revenue increased slightly by growth in accelerator and fusion technologies at our Research Instruments (“RI”) business which is gaining traction in extreme ultraviolet lithography technologies for next-gen semiconductors, and was mostly offset by softness in clinical MRI superconductors. business.
Paragraph 53 · 47% changed
Our research and development expenses for the year ended December 31, 2024, 2025, increased to 11.2% 11.5% of total revenue from 9.9% 11.2% of total revenue for the comparable period in 2023. 2024. We commit substantial resources, efforts, and capital to internal and collaborative research and development projects in order to provide innovative products and solutions to our customers. Additionally, we have been able to gain access to research and development capabilities through acquisitions, acquiring the intellectual property, technology, and expertise of the acquired companies. The increase in research and development costs as a percentage of revenue is was primarily a result of our increased investment in research and development capabilities, and the mix of research and developments costs from 2024 associated with prior year acquisitions. Investments are primarily related to additional headcount and personnel expenses as well as increased consulting and professional fees related to research and development activities.
Paragraph 72 · 42% changed
The decrease in consolidated net income adjusted for non-cash items was primarily due to driven by lower income as a result of unfavorable margin revenue mix combined with negative impact of new U.S. trade tariffs and increased costs foreign exchange headwinds from a declining U.S. Dollar, and timing of income taxes payable partially offset by the non-cash impairment charges related to 2024 acquisitions. goodwill and intangible assets primarily in our BSI BioSpin and BSI NANO segments. The decrease in the change in operating assets and liabilities, net of acquisitions was increased primarily due to higher inventory balances to handle supply chain challenges, higher accounts receivable decreased accrued compensation costs as a result of cost-saving initiatives and lower deferred revenue and customer advances, timing of income taxes payable, partially offset by increases an increase in accounts payable working capital including higher receivables and accrued expenses inventory levels.
Paragraph 52 · 42% changed
Our selling, general and administrative expenses for the year ended December 31, 2024, 2025, increased to 26.6% 27.5% of total revenue from 24.6% 26.6% of total revenue for the comparable period in 2023. 2024. The year over year year-over-year increase as a percentage of revenue was primarily due to increased costs associated with prior year acquisitions and foreign exchange headwinds from a result declining U.S. Dollar, partially offset by the impact of increased mix of sales and marketing costs from 2024 acquisitions, increased spending related to additional headcount and personnel expenses, as well as increased consulting and professional fees related to acquisitions, tax, audit and audit-related fees. cost savings initiatives.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A252 words changed in this paragraph; it is 38% similar to last year's version.
Net cash provided by financing activities during the year ended December 31, 2025, was primarily from net proceeds from the issuance of Series A Mandatory Convertible Preferred Stock, net of issuance costs of $669.7 million, offset by net repayment of our revolving line of credit of $28.3 million, repayments of long-term debt of $466.5 million (refer to Note 20, Debt), the payment of dividends to common and preferred shareholders of $32.9 million and cash paid for purchases of common stock under our repurchase program of $10.0 million. Net cash used in financing activities during the year ended December 31, 2024, was primarily from proceeds from long-term debt of $973.7 million (refer to Note 21, Debt), million, proceeds from our public offering of common stock of $403.0 million (refer to Note 27, Shareholders’ Equity), million, and net proceeds from our revolving line of credit of $37.6 million (refer to Note 21, Debt). These inflows were million, primarily offset by the repayment of our 2012 Note Purchase Agreement purchase agreement of $100.0 million and the payment of dividends to common shareholders of $30.2 million. The increase in During the year ended December 31, 2025, we raised proceeds via the issuance of equity financing and via the net increase in issuance of the Series A Mandatory Convertible Preferred Stock to pay down some of our outstanding debt financing was primarily due to acquisition activity. Net cash used in financing activities obligations, whereas during the year ended December 31, 2023, was primarily attributable 2024, we raised proceeds via the issuance of equity via our public offering and entered into new debt obligations for strategic acquisitions. As a result of the Series A Mandatory Convertible Preferred Stock issuance, we also have certain obligations with respect to cash payments made discretionary dividends to our preferred shareholders in addition to the discretionary dividends historically paid to our for shares of our common stock under our repurchase program of $152.3 million, and $29.4 million for the payment of dividends. shareholders.

Source: Item 7, 10-K 0001193125-26-082523 vs Item 7, 10-K 0000950170-25-030897

Risk Factors221 words changed in this paragraph; it is 41% similar to last year's version.
We have experienced supply chain interruptions or increased costs as a result of general global economic conditions, including economic instability, changes to governmental policies and programs, changes in tax laws and regulations, export controls, economic sanctions and trade restrictions, including those related to the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, changes to trade policies, including higher tariff rates and customs duties imposed or that may be imposed by the new presidential administration in the U.S., continued threat of terrorism and heightened security and military action in response thereto, or any other current or future acts of terrorism, war (such as the ongoing geopolitical tensions and military conflicts in China and other regions between the U.S. and China ), a tight labor market and other factors, including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in our products including microelectronic components and increased difficulties in our ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in our products, including limited source components, have and can result in significant additional costs and inefficiencies in manufacturing. A shortage of key components has in the past and may in the future cause a significant disruption to our production activities, which could have a substantial adverse effect on our financial condition or results of operations. If we are unsuccessful in resolving any such component shortages in a timely manner, we could experience a significant adverse impact on the timing of our revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which could have a material adverse impact on our operating results.

Source: Item 1A, 10-K 0001193125-26-082523 vs Item 1A, 10-K 0000950170-25-030897

Legal Proceedings152 words changed in this paragraph; it is 46% similar to last year's version.
In connection with the Company’s acquisition of PhenomeX Inc. (“PhenomeX”) on October 2, 2023, the Company’s wholly owned subsidiary, Bruker Cellular Analysis, Inc. (“BCA”), Inc., was substituted as a party into the existing patent litigation between PhenomeX and AbCellera Biologics Inc Inc. (“AbCellera”) related to PhenomeX’s Beacon instruments and Opto Optofluidic platform products. The University of British Columbia (“UBC”), the owner and licensor to AbCellera of the asserted patents, is was a co-plaintiff in the litigation. On December 17, 2025, the Company, AbCellera, and UBC entered into a settlement and patent license agreement resolving the patent litigation globally. The plaintiffs’ complaint seeks unspecified damages settlement includes an agreement by the Company to pay $36.0 million to AbCellera in the first two quarters of 2026. In addition, effective as of the settlement date, the Company will pay royalties on sales of Bruker’s Beacon Optofluidic platform products in designated market segments until the expiration of the applicable licensed patents. In accounting for the settlement agreement, the Company recognized an intangible asset related to the patent license agreement and injunctive relief. recorded the remaining settlement amount under other current liabilities in the consolidated balance sheets in the fourth quarter of 2025. Refer to Note 19, Other Current and Long-term Liabilities for more information on the amounts included within other current liabilities.

Source: Item 3, via Note 25 – Commitments and Contingencies, 10-K 0001193125-26-082523 vs Item 3, via Note 26 – Commitments and Contingencies, 10-K 0000950170-25-030897

Accounting Policies141 words changed in this paragraph; it is 75% similar to last year's version.
The Company tests goodwill for impairment annually as of October 1 or more frequently if impairment indicators arise at the reporting unit level, which is the operating segment or one level below an operating segment. The Company has the option of performing a qualitative assessment to determine whether further impairment testing is necessary before performing the quantitative assessment. If as a result of the qualitative assessment, it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, a quantitative impairment test will be required. Otherwise, no further testing will be required. If a quantitative impairment test is performed, the Company compares the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. The Company determines the fair value of reporting units using a weighting of both the market and the income methodologies approach. The income approach utilizes a discounted cash flow model with inputs developed using both internal and has classified it as Level 3 in market-based data, while the fair value hierarchy. market approach utilizes comparable company information. Estimating the fair value of the reporting units requires significant judgment by management. The Company develops the significant assumptions in the discounted cash flow models by considering current market conditions and future expectations which may include new product and service developments, impact of competition, and future economic conditions. These estimates and assumptions represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized for the amount by which the carrying value amount exceeds the reporting unit’s fair value up to the total amount of goodwill allocated to the reporting unit. No During the year ended December 31, 2025, the Company recorded goodwill impairment of losses for certain reporting units as disclosed in Note 6, Goodwill and Intangible Assets. The Company recorded no goodwill or indefinite-lived assets was recognized during impairment for the years ended December 31, 2024, 2023, or 2022. and 2023.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001193125-26-082523 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0000950170-25-030897

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of BRKR's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Mar 3, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, including as a result of the recent U.S. Supreme Court decision, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future;
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
•Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future;
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
•Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Recently, the U.S. government has indicated its intent to modify U.S. trade policy and, in some cases, to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements. It has also imposed or increased tariffs on foreign imports into the United States from key trading partners, including Germany and Switzerland.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
The tariff increases adopted in 2025, and the uncertainty associated with them in global markets, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability, and may continue to
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
adversely affect our business, results of operations and financial condition for the foreseeable future. For example, during the year ended December 31, 2025, our results of operations were adversely impacted by an increase in cost of goods sold as a result of increased tariffs. Changes to tariffs and trade policies between the United States and foreign countries, such as what occurred during 2025, could reduce the purchasing power of our customers by increasing costs in their operations, which in turn may lead to decreased demand for our products or services. The magnitude and duration of any reduction in customer purchasing ability is difficult to reliably predict and quantify.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Moreover, tariffs and international trade arrangements may continue to change, potentially without warning, and to an extent that is difficult to predict. On February 20, 2026, the U.S. Supreme Court issued a ruling striking down certain tariffs previously imposed under the International Emergency Economic Powers Act (“IEEPA”). The ultimate availability, timing, and amount of any potential refunds of such tariffs remain highly uncertain and are subject to further legal, regulatory, and administrative developments. Following the Supreme Court’s decision, the U.S. presidential administration announced its intention to invoke other laws to collect tariffs and announced new tariffs on imports from all countries, in addition to any existing non-IEEPA tariffs.
Read it in 10-K Feb 27, 2026 at sec.gov
Show the other 64
AddedRisk Factors
There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may be imposed, modified, or suspended, and the impacts of such actions on our business. We are continuing to monitor and evaluate these “developments” and assess their potential impact on our business, financial condition, and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
A significant portion of our revenue is derived from sales into China, some of which are directly funded through Chinese government stimulus programs for high-end medical and industrial research instrumentation. In 2025, the release of such Chinese government stimulus spending was delayed, which has negatively affected our sales growth into China and consequently has had an adverse effect on our business, results of operations, and financial condition in 2025. Our revenue in China for the year ended December 31, 2025, was $475.8 million and remained flat compared to $471.2 million for the year ended December 31, 2024. If the release of the Chinese government’s stimulus spending continues to be delayed or recurs, our sales into China may continue to be negatively affected and our business, results of operations, and financial condition may be adversely affected in the foreseeable future. Furthermore, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. In addition to tariffs newly imposed by the U.S. and China, which have fluctuated and remain volatile, and may increase our costs, there may be additional import, export, tax, or other regulatory changes effected by the U.S. and Chinese governments in the future that could also adversely affect our business and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
Our businesses and results of operations are affected by international, national and regional economic and political conditions. Our businesses or financial results may be adversely impacted by unfavorable changes in economic or political conditions in the countries and markets in which we operate, including, among others, adverse changes in interest rates or tax rates, volatility in financial and commodity markets, contraction in the availability of credit in the marketplace, higher tariffs, including those that have been or may be imposed by the new presidential administration in the U.S., armed hostilities, such as the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, and other events related thereto, such as economic sanctions and trade restrictions, geopolitical tensions, including tensions in China and other regions, changes in capital spending patterns, and renegotiation of existing trade agreements in the United States or countries that could adversely affect our supply chain and our business.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
The new U.S. presidential administration has imposed or threatened to impose tariffs ranging from 10-25% on a variety of countries, including China, Mexico, Canada and the EU, and products, including steel, aluminum, copper, automobiles, and digital services, and is likely to continue to do so in the future. In addition, the U.S. has threatened the imposition of reciprocal tariffs on those countries who impose unequal tariffs or taxes on U.S. exports. While to date, the only tariff increase in effect is the additional 10% tariff on U.S. imports from China, which is potentially increasing to 20% on March 4, 2025, there is no guarantee that other threatened tariff increases will not become effective in the future. Given the current uncertainty around the threat of tariff increases, it is not possible to estimate the potential effect or to determine the level of materiality to the Company. Such tariff increases, if adopted and applicable to U.S. imports by the Company or its suppliers, could result in increased costs, including potential costs related to shifting more production to the U.S. or other countries, that might be material to the Company.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
The United States has implemented tariffs on certain imported goods and the new presidential administration in the US has imposed or threatened to impose additional tariffs on certain imported products, including reciprocal tariffs. These additional tariffs could include items imported by us from China or other countries. In addition, China has imposed tariffs on a wide range of American products in retaliation for these new American tariffs. As a result, there is a concern that the imposition of additional tariffs by the United States could result in the adoption of additional tariffs by China and other countries as well. Any resulting trade war could negatively impact the global market for scientific instruments and could have a significant adverse effect on our business. The imposition of tariffs on items imported by us from China or other countries could increase our costs and could result in lowering our gross margin on products sold. Conversely, any imposition by China of tariffs on items that we export to China could adversely impact our customers’ ability to purchase our products and our competitive position in China or increase our costs, which could have a material adverse effect on our business and results of operations.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
Decentralization necessarily places significant control and decision-making powers in the hands of local management, which presents certain risks, including the risk that we may be slower to detect or react to compliance-related matters and that “company-wide” business initiatives may be more challenging or costly to implement, and the risk of noncompliance or failures higher than they may be in a more centralized operating environment. In addition, key business group resources and our corporate functions responsible for supporting our decentralized operations, may also not be able to detect or resolve financial, operational, and compliance matters on a timely basis. Our failure to adapt our financial, operational and compliance controls and systems to effectively manage our decentralized business and comply with our obligations as a public company could materially and adversely affect our business, financial condition or results of operations.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedRisk Factors
We have experienced supply chain interruptions or increased costs as a result of general global economic conditions, including economic instability, changes to governmental policies and programs, changes in tax laws and regulations, export controls, economic sanctions and trade restrictions, including those related to the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, changes to trade policies, including higher tariff rates and customs duties imposed or that may be imposed by the new presidential administration in the U.S., continued threat of terrorism and heightened security and military action in response thereto, or any other current or future acts of terrorism, war (such as the ongoing geopolitical tensions and military conflicts in China and other regions between the U.S. and China ), a tight labor market and other factors, including natural events and disasters.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Most of our outstanding debt is in the United States and there are We have substantial cash requirements funding obligations in the United States to service debt interest obligations, fund operations, capital expenditures expenditures, and our declared dividends on our common stock and finance potential acquisitions or share repurchases. our dividends on the Series A Mandatory Convertible Preferred Stock.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding, including NIH grants, NIH, NSF and any reduction in, modification of the terms and allowable overhead rates of, or delay in such research funding, could adversely affect our U.S. academic and governmental customers, and our revenues and financial performance. DOE grants.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Economic factors that could adversely influence demand for our products include the impact of geopolitical tensions and any related sanctions implemented, continued uncertainty about global economic conditions, including as a result of any natural disasters, pandemics, or epidemics, leading to ongoing reductions in investment, changes in government spending levels and/or priorities, the size and availability of government budgets, customers’ and suppliers’ access to credit and other macroeconomic factors affecting government, academic or industrial spending behavior.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We recorded net losses gains from currency translation adjustments of $115.1 million for the year ended December 31, 2025, and net losses of $79.6 million during the year ended December 31, 2024, and net gains of $76.2 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If we experience any significant disruption of those facilities for any reason, such as war or other geopolitical conflicts, strikes or other labor unrest, power interruptions, fire, earthquakes, or other events beyond our control, we may be unable to manufacture the relevant products at previous levels or at all.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If U.S, U.S. academic and governmental researchers experience experiencing material reductions or delays in government funding, or modifications of the terms or conditions of funding, including allowable overhead rates, they may reduce have reduced or delay delayed their purchases of our products and services, which could have a material effect on has adversely affected our revenues business and financial performance. results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
However, During the year ended December 31, 2025, the Company recorded an impairment loss losses for certain goodwill and intangible assets and certain right of use assets as disclosed in Note 12, Restructuring 6, Goodwill and asset impairments Intangible Assets to our consolidated financial statements included in Item 8 of this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The effects of changes in currency exchange rates increased our 2025 revenue by approximately $77.6 million, or 2.3%, decreased our 2024 revenue by approximately $13.1 million, or 0.4%, and increased our 2023 revenue by approximately $11.2 million, or 0.4%, and decreased our 2022 revenue by approximately $168.0 million, or 6.9%. 0.4%.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
These policies are based on a wide variety of factors, including the resources available to make purchases, the spending priorities among various types of equipment, policies regarding spending during recessionary periods, changes in the political climate, including disruptions or changes to funding of other government agencies, changes to governmental policies and programs, including loans, grants, guarantees and other subsidies, and changes to government spending policies, including shifts in funding priorities.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
When We are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these remaining countries; however, when and how this framework is adopted or enacted by the various countries in which we do business will increase tax complexity and may increase uncertainty and adversely affect our provision for income taxes in the U.S. and non-U.S. jurisdictions.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The following risk factors should be considered in conjunction with the other information included in this Annual Report on Form 10-K. 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
If this any data is compromised, destroyed or inappropriately disclosed, it could have a material adverse effect, including damage to our reputation, and our relationships with our employees, customers, suppliers and other business partners, decrease the value of our investments in research, development and engineering, disrupt our manufacturing processes, result in significant expenses to address and resolve the issues, fines or litigation or other proceedings by affected individuals, customers, suppliers, business partners or regulatory authorities.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The non-GAAP CER revenue decline during the year ended December 31, 2025, was driven primarily by slower demand in industrial and semiconductor markets for our analytical instruments, partially offset by higher revenue from hospital and clinical markets as well as the current year impact of recent acquisitions.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The decrease in non-GAAP gross profit and gross profit margin during the year ended December 31, 2025, was driven by an increase in cost of goods sold due to higher U.S. tariffs, foreign exchange headwinds from a declining U.S. Dollar, and the overall revenue mix, partially offset by the impact of cost savings initiatives.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Year Ended December 31, 2025 2024 Operating income $ 68.2 2.0 $ 253.1 7.5% Non-GAAP adjustments: Restructuring costs 77.4 2.3 24.7 0.7% Acquisition-related costs 16.3 0.5 51.9 1.5% Acquired in-process research and development expenses 13.5 0.4 — — Acquisition-related hybrid liability adjustments (50.2) (1.5 24.1 0.8% Purchased intangible amortization 121.2 3.5 99.1 2.9% Acquisition-related litigation charges 35.3 1.0 46.0 1.4% Goodwill and intangible assets impairment charges 127.2 3.7 0.4 — Other costs 24.2 0.7 18.7 0.6% Non-GAAP operating income $ 433.1 12.6 $ 518.0 15.4%
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The decrease in our non-GAAP operating margins during the year ended December 31, 2025, was driven primarily by lower non-GAAP gross profit, the impact of foreign currency translation, and the impact of our 2024 acquisitions, partially offset by cost savings initiatives.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Historically, we have higher levels of revenue in the fourth quarter and lower levels of revenues in the first quarter of the year, which we believe is influenced by our customers’ budgeting cycles.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The decrease in total gross profit and gross profit margin during the year ended December 31, 2025, was driven primarily by declines in the BSI BioSpin UHF business and the Nano Surfaces and Metrology division, combined with increased restructuring costs and impairment charges as well as the impact of U.S. tariffs and foreign exchange headwinds from a declining U.S. Dollar.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We test goodwill for impairment annually as of October 1 or more frequently if impairment indicators arise at the reporting unit level, which is the operating segment or one level below an operating segment. Due to the current macroeconomic conditions and uncertainties related to the future forecasts, the Company concluded that it was more likely than not that the fair value of one or more of the Company’s reporting units was less than their carrying amount. As a result, the Company performed a quantitative impairment test for impairment in certain reporting units as of September 30, 2025, as these reporting units had the highest uncertainty related to quantity and timing of future cash flows. As these conditions existed as of the balance sheet date, any impairment charges are recognized in the consolidated statements of operations for the period ended September 30, 2025. The results of the valuation indicated that the carrying amount of the Bruker Spatial Biology (“BSB”) reporting unit within the Company’s BSI NANO Segment and Automation (“AUT”) reporting unit within the Company’s BSI BioSpin Segment exceeded their fair value. As a result, during the year ended December 31, 2025, the Company recorded a goodwill impairment charge of $96.5 million on the consolidated statements of operations, which represented the amount by which the carrying value of the BSB reporting unit and AUT reporting unit exceeded the respective reporting unit’s fair value.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
While we will continue to monitor these circumstances, such uncertainties, including the current macroeconomic conditions and the timing and quantity of future cash flows may impact the carrying value of our reporting units. If there are any factors that drive changes to key assumptions in our valuation inputs and if the fair value of any of our reporting units declines below the carrying value in the future, additional goodwill impairment charges may be incurred and those charges may be material. Refer to Note 6, Goodwill and Intangible Assets for further information on our goodwill impairment.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The decrease in total operating income and operating income margin was primarily due to unfavorable revenue mix which negatively impacted gross margins, increased restructuring costs and impairment charges, the impact of U.S. tariffs, and foreign exchange headwinds from a declining U.S. Dollar. In August 2025, we announced a cost savings initiative aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026. This cost savings initiative was implemented with the intention to improve operating income and operating margins on a company-wide basis. The planned reductions affect all parts of our business including supply chain, manufacturing, commercial operations, administrative functions and research and development.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Recently, the U.S. government has indicated its intent to modify U.S. trade policy and, in some cases, to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements. It has also imposed or increased tariffs on foreign imports into the United States from key trading partners, including Germany and Switzerland.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The tariff increases adopted in 2025, and the uncertainty associated with them in global markets, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability, and may continue to adversely affect our business, results of operations and financial condition for the foreseeable future. For example, during the year ended December 31, 2025, our results of operations were adversely impacted by an increase in cost of goods sold as a result of increased tariffs. Changes to tariffs and trade policies between the United States and foreign countries, such as what occurred during 2025, could reduce the purchasing power of our customers by increasing costs in their operations, which in turn may lead to decreased demand for our products or services. The magnitude and duration of any reduction in customer purchasing ability is difficult to reliably predict and quantify.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Moreover, tariffs and international trade arrangements may continue to change, potentially without warning, and to an extent that is difficult to predict. On February 20, 2026, the U.S. Supreme Court issued a ruling striking down certain tariffs previously imposed under the International Emergency Economic Powers Act (“IEEPA”). The ultimate availability, timing, and amount of any potential refunds of such tariffs remain highly uncertain and are subject to further legal, regulatory, and administrative developments. Following the Supreme Court’s decision, the U.S. presidential administration announced its intention to invoke other laws to collect tariffs and announced new tariffs on imports from all countries, in addition to any existing non-IEEPA tariffs.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
During the fiscal year ended December 31, 2024, Bruker made several acquisitions including ELITechGroup, NanoString and Chemspeed. These acquisitions enable Bruker to extend our capabilities in molecular diagnostics (ELITechGroup), life science analytical instruments (NanoString) and to provide new capabilities in lab automation (Chemspeed). Refer to Note 4, Acquisitions in the consolidated financial statements.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The decrease in non-GAAP CER revenue growth was driven primarily by lower growth in our academic, government, and industrial markets against difficult high growth comparables in 2023. China was also a significant contributor to our slower growth in 2024 compared to the prior year. These markets were offset by revenue from acquisitions and organic growth.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The increase in gross profit was a result of pricing and volume leverage, marginally offset by net unfavorable impact of foreign exchange rate movements compared to 2023. The decrease in gross profit margin was primarily due to mix impact of our 2024 acquisitions combined, and unfavorable foreign exchange rate movements.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The decrease in operating income and operating income margin was primarily due to unfavorable margin mix and increased costs related to 2024 acquisitions, and unfavorable foreign exchange rate movements.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
In 2023, the Company recorded a gain of $144.1 million, in connection with the PhenomeX acquisition, which closed on October 2, 2023. This bargain purchase gain reflected the excess of identifiable net assets acquired, including deferred tax assets related to acquired tax NOLs, over the purchase consideration paid.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
In 2024, following the finalization of a review of income tax positions related to change in ownership limitations assessments on NOL/R&D credits at the end of the business combination measurement period in connection with the PhenomeX acquisition, the Company recorded a charge of $8.0 million
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The decrease in net income and earnings per diluted share was primarily driven by lower gross and operating margins, higher tax rate, as well as the bargain purchase gain recognized in 2023 in connection with the PhenomeX acquisition.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Effective in the quarter ended June 30, 2024, the Company entered into a multi-currency notional cash pooling agreement with a financial institution to manage cash flow more efficiently and optimize liquidity. Refer to Note 2, Summary of Significant Accounting policies for more information on our notional cash pooling agreement.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedMD&A
Selling, general and administrative 946.5 893.8 729.4 164.4 22.5 52.7 5.9 Research and development 395.2 376.5 294.8 81.7 27.7 18.7 5.0 Goodwill impairment charge 96.5 — 96.5 100.0 Other charges, net 71.3 126.1 52.2 73.9 141.6 (54.8) (43.5 Total operating expenses 1,509.5 1,396.4 1,076.4 320.0 29.7 113.1 8.1 Operating income 68.2 253.1 436.9 (183.8) (42.1 (184.9) (73.1 Bargain purchase gain and associated measurement period adjustments — (8.0) 144.1 (152.1) (105.6 8.0 100.0 Interest and other income (expense), expense, net (46.2) (38.2) (36.8) (1.4) 3.8 (8.0) 20.9 Income before income taxes, equity in income (losses) losses of unconsolidated 22.0 206.9 544.2 (337.3) (62.0 unconsolidated (184.9) (89.4 investees, net of tax, and noncontrolling interests in consolidated subsidiaries Income tax provision 29.3 91.4 117.7 (26.3) (22.3 (62.1) (67.9 Equity in income (losses) losses of unconsolidated investees, net of tax (1.0) (1.7) 2.0 (3.7) (185.0 0.7 (41.2 Consolidated net (loss) income (8.3) 113.8 428.5 (314.7) (73.4 (122.1) (107.3 Net income attributable to noncontrolling interests in 0.3 0.7 1.3 (0.6) (46.2 (0.4) (57.1 consolidated subsidiaries Net (loss) income attributable to Bruker Corporation (8.6) 113.1 (121.7) (107.6 Dividends on Series A Mandatory Convertible Preferred Stock 13.9 — 13.9 100.0 Net (loss) income attributable to Bruker Corporation common shareholders $(22.5) $113.1 $427.2 $(314.1) (73.5 (135.6) (119.9
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
We After consideration of the debt repayments made with the proceeds from the Series A Mandatory Convertible Preferred Stock described above, along with $141.5 million paydown of the 2024 term loan due in 2027 during the fourth quarter of 2025, we have a total outstanding debt of $2.1 $1.9 billion as of December 31, 2024, 2025, and a revolving credit facility that provides for up to $900.0 million of additional backup liquidity to finance working capital needs, refinance or reduce existing indebtedness, and for general corporate use use, of which $872.2 $899.3 million is undrawn. available.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Non-GAAP Constant-exchange rate (CER) (“CER”) currency revenue 3,379.5 2,953.3 $3,358.9 $3,379.5 Non-GAAP Constant-exchange rate (CER) (“CER”) currency revenue year-on-year (decrease) growth rate (0.2 14.0% 16.7% Non-GAAP Organic Revenue $3,242.6 $3,082.8 Non-GAAP Organic Revenue year-on-year (decrease) growth rate compared to prior year revenue (3.7 4.0% Non-GAAP Gross Profit 1,736.9 1,547.6 $1,712.0 $1,736.9 Non-GAAP Gross Profit Margin 49.8 51.6% 52.2% Non-GAAP Operating Income 518.0 546.3 $433.1 $518.0 Non-GAAP Operating Income Margin 12.6 15.4% 18.4% Non-GAAP Free Cash Flow 136.0 243.2 $43.3 $136.0
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Net cash provided by used in financing activities during the year ended December 31, 2024, was primarily from proceeds from long-term debt of $973.7 million (refer to Note 21, Debt), million, proceeds from our public offering of common stock of $403.0 million (refer to Note 27, Shareholders’ Equity), million, and net proceeds from our revolving line of credit of $37.6 million, primarily offset by the repayment of our 2012 Note purchase agreement of $100.0 million (refer and the payment of dividends to Note 21, Debt). common shareholders of $30.2 million.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Dollar Percentage Change Change Product revenue $2,766.4 $2,759.2 $2,457.6 $301.6 12.3 $7.2 0.3 Service and other revenue 670.1 607.2 506.9 100.3 19.8 62.9 10.4 Total revenue 3,436.5 3,366.4 2,964.5 401.9 13.6 70.1 2.1 Cost of product revenue 1,486.5 1,364.5 1,165.2 199.3 17.1 122.0 8.9 Cost of service and other revenue 372.3 352.4 286.0 66.4 23.2 19.9 5.6 Total cost of revenue 1,858.8 1,716.9 1,451.2 265.7 18.3 141.9 8.3 Gross profit 1,577.7 1,649.5 1,513.3 136.2 9.0 (71.8) (4.4 Operating expenses:
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Although our consolidated financial statements have been prepared in accordance with GAAP, we believe that describing revenue excluding the effects of foreign currency, and expenses excluding costs related to restructuring actions, acquisition impairment costs, acquisitions, integration and related integration IT transformation expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other costs (“non-GAAP adjustments”), provides meaningful supplemental information regarding our performance. performance but should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Year ended Ended December 31, 2025 2024 2023 GAAP revenue $ 3,366.4 $ 2,964.5 3,436.5 $3,366.4 Effect of changes in foreign currency translation rates (77.6) 13.1 (11.2) Non-GAAP CER currency revenue $ 3,379.5 3,358.9 $3,379.5 Acquisitions 116.3 296.7 Non-GAAP Organic revenue $ 2,953.3 GAAP Revenue growth rate 13.6% 17.1% Non-GAAP CER currency revenue growth rate 14.0% 16.7% 3,242.6 $3,082.8
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Historically, we have financed our growth and used the liquidity needs through generated from cash flow generation from operations and a combination of operations, debt financings financings, and issuances of common stock. and preferred stock to finance our growth and operating needs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Revenue $ 3,366.4 $ 2,964.5 $3,436.5 $3,366.4 Revenue year-on-year Growth Rate 2.1 13.6% 17.1% Gross Profit 1,649.5 1,513.3 $1,577.7 $1,649.5 Gross Profit Margin 45.9 49.0% 51.0% Operating Income 253.1 436.9 $68.2 $253.1 Operating Income Margin 2.0 7.5% 14.7% Net cash provided by operating activities 251.3 350.1 $134.1 $251.3 Non-GAAP Financial Measures (see 'Non-GAAP Measures' “Non-GAAP Measures” below):
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The decrease in consolidated net income adjusted for non-cash items was primarily due to driven by lower income as a result of unfavorable margin revenue mix combined with negative impact of new U.S. trade tariffs and increased costs related to 2024 acquisitions. foreign exchange headwinds from a declining U.S.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, 2025, our free cash flow was $107.2 decreased by $92.7 million lower than compared to the same period in 2023, 2024, primarily due to lower net income and significant acquisition-related expenses. an increase in tax payments in 2025.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Bruker is organized into four reportable segments: the Bruker Scientific Instruments (BSI) BSI BioSpin Segment, the BSI CALID Segment, the BSI NANO Segment Segment, and the Bruker Energy & Supercon Technologies (BEST) BEST Segment.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesMD&A
Net cash provided by operating activities during the year ended December 31, 2024, resulted primarily from consolidated net income adjusted for non-cash items of $329.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions of $78.2 million.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.